LABS, Inc. Announces HCT/P ZIKA Virus Screening of Living Donors

Share Article

LABS, Inc. announces Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/P) ZIKA Virus screening of living, or "heart beating" donors.

News Image
At LABS, we look beyond the testing to what is possible as a result of it.

LABS, Inc. (LABS) announced in December 2016 that two new Zika Virus (ZIKV) test offerings were added to its extensive test menu: Nucleic Acid Testing (NAT) for ZIKV; and Enzyme Immunoassays (EIAs) specific for IgM and IgG ZIKV antibodies. At that time, LABS was only able to offer NAT screening for blood donors under an Investigational New Drug (IND) study protocol.

Now, as part of an ongoing commitment to enabling customers’ safe and timely decisions by delivering the highest quality, most accurate laboratory services, LABS is pleased to announce a third ZIKV test offering. LABS is participating in a second IND, with Grifols, a leader in the lab assay market, which will encompass HCT/P screening of living, or “heart-beating” donors. The results are to be used for Investigational Use Only and are not to be used to aid in diagnosis. While the healthcare community awaits final FDA Guidelines, this IND ZIKV option is intended to provide LABS customers with the most up-to-date products and services. If your organization is interested in ZIKV testing, please contact LABS.

For additional information about ZIKV, please visit the U.S. Food and Drug Administration or Centers for Disease Control and Prevention.

About LABS, Inc.
Founded in 1978, LABS provides laboratory services specialized for transplantation and biomedical applications. Our mission is to enable customers’ safe and timely decisions by delivering the highest quality, most accurate laboratory services. We hold an extensive list of registrations, accreditations and licensures including the American Association of Blood Banks (AABB), Clinical Laboratory Improvement Amendments (CLIA), and the U.S. Food and Drug Administration (FDA). We combine our industry-leading credentials with a customer consultative approach to deliver precisely what’s needed, when and how it’s needed. As a result, our customers are able to make safe, informed and prompt decisions that impact their business, and the lives of those they serve. At LABS, we look beyond the testing to what is possible as the result of it. Lives are at stake, innovation is impacted and potential is effected. What we do matters, but what our customers do with it matters even more. LABS. Realize the potential. For more information, please visit our website.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Emily Yeingst
LABS, Inc.
+1 720.528.4722
Email >
Visit website